Viking Therapeutics (VKTX) Shares Outstanding (2014 - 2026)

Viking Therapeutics has reported Shares Outstanding (Entity) for 13 years, with the latest figure at $116.7 million in Q2 2026.

• Quarterly Shares Outstanding (Entity) rose 3.85% year-over-year to $116.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $116.7 million (up 3.85% YoY) and the FY2025 annual result came in at $114.8 million, up 2.89% from the prior year.
• Shares Outstanding (Entity) climbed to $116.7 million in Q2 2026 per VKTX's latest filing, from $115.9 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $116.7 million in Q2 2026 and troughed at $76.7 million in Q2 2022.
• A 5-year average of $100.9 million and a median of $110.5 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) declined 1.98% in 2022, then surged 38.97% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $78.3 million in 2022, then gained by 27.93% to $100.1 million in 2023, then rose by 11.45% to $111.6 million in 2024, then advanced by 2.89% to $114.8 million in 2025, then climbed by 1.62% to $116.7 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $116.7 million, $115.9 million, and $114.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.